by Sam Eskandari | Jun 6, 2017 | News
June 6, 2017, Vancouver, B.C. – Veritas Pharma Inc. (CSE: VRT; OTC: VRTHF; and Frankfurt: 2VP), as an ACMPR applicant would like to notify its investors that Health Canada is introducing several improvements that aim to streamline the ACMPR licensing process....
by Sam Eskandari | May 30, 2017 | News
May 30, 2017, Vancouver, B.C. – Veritas Pharma Inc. (CSE: VRT; OTC: VRTHF; and Frankfurt: 2VP) is pleased to announce that Cannevert Therapeutic Ltd.’s development of its medicinal cannabis pipeline has expanded to include anti-emesis (anti-nausea/vomiting) therapies....
by Sam Eskandari | May 17, 2017 | News
May 17, 2017, Vancouver, B.C. – Veritas Pharma Inc. (CSE: VRT; OTC: VRTHF; and Frankfurt: 2VP), an emerging discovery and IP development company, is pleased to announce the appointment of David Greenway as a Director of the Company. Mr. Greenway has two decades of...
by Sam Eskandari | May 8, 2017 | News
May 8, 2017, Vancouver, B.C. – Veritas Pharma Inc. (CSE: VRT; OTC: VRTHF; and Frankfurt: 2VP), an emerging discovery and IP development company, is pleased to announce that its research arm, Cannevert Therapeutics Ltd. is moving swiftly towards properly certified and...
by Sam Eskandari | Mar 14, 2017 | News
March 15, 2017, Vancouver, B.C. – Veritas Pharma Inc. “Veritas” (CSE: VRT; OTC: VRTHF; and Frankfurt: 2VP), an emerging discovery and IP development company, is pleased to announce that it has entered into an agreement with AlphaPheno Inc....
